

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:	Serge Louis Boulet et al.	Group Art Unit: 1626
Serial No.:	10/597,835	Sun Jae Y Loewe
Application Date:	February 18, 2005	Conf No.: 6937
US Nat'l Entry		
Date (if applicable):	August 9, 2006	
For:	PHARMACEUTICAL COMPOUNDS	
Docket No.:	X-16288	

STATEMENT UNDER 37 CFR 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit the following statement under §1.97(e):

I, Mark A. Winter, hereby state that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Applicants request consideration of this information.

Respectfully submitted,
/Mark A. Winter/

Mark A. Winter
Agent for Applicants
Registration No. 53,782
Phone: 317-276-5362

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
September 11, 2008
